# EDGAR Filing Document

**Accession Number:** 0001652935
**File Stem:** 0000000000-25-009111
**Filing Date:** 2025-8
**Character Count:** 2500
**Document Hash:** 1ec5bf78fe35c1fcd9ab729b1ca19b63
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009111.hdr.sgml**: 20251203

**ACCESSION NUMBER**: 0000000000-25-009111

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250826

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ACTUATE THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001652935
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473044785
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08342

**BUSINESS ADDRESS:**
- **STREET 1:** 1751 RIVER RUN
- **STREET 2:** SUITE 400
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76107
- **BUSINESS PHONE:** 847-986-4190

**MAIL ADDRESS:**
- **STREET 1:** 1751 RIVER RUN
- **STREET 2:** SUITE 400
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Apotheca Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20150911
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001683168-25-006280

## Text-Extract

```

                                                            August 26, 2025

Daniel Schmitt
President and Chief Executive Officer
Actuate Therapeutics, Inc.
1751 River Run, Suite 400
Fort Worth, Texas 76107

       Re: Actuate Therapeutics, Inc.
           Draft Registration Statement on Form S-3
           Submitted August 18, 2025
           CIK No. 0001652935
Dear Daniel Schmitt:

       This is to advise you that we do not intend to review your registration
statement.

        We request that you publicly file your registration statement and
non-public draft
submission on EDGAR at least two business days prior to the requested effective
date and
time. Please refer to Rules 460 and 461 regarding requests for acceleration. We
remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Janet Spreen, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._